$0.48—Stale · unknown old
STO • Last print unknown ago
$0.48—Stale · unknown old
9/28/26
Neola Medical AB (publ) (NEOLA.ST)
Monday
6:43 AM
ThesisConcerns over competitive threats and the lack of revenue generation are dampening investor sentiment despite potential growth opportunities.
Revenue Outlook
What Moves the Stock
- 01Regulatory approvals for new medical devices
- 02Partnership announcements with healthcare providers
- 03Clinical trial results demonstrating efficacy of products
- 04Market expansion into new European countries
- 05Sales of respiratory medical devices - 100%
- 06Telehealth integration in respiratory care
- 07Increased focus on patient-centric medical devices
FY2025 Snapshot
- Revenue
- $0.00
- Gross Margin
- 0.0%
- Op. Margin
- 0.0%
- Net Margin
- 0.0%
- Net Income
- $-11M
- NI Growth
- -9.5%
- EPS
- $-0.14
- 1Y Return
- -77.3%
NEOLA.ST Chart
My Notes
- "The market is cautious as we navigate a challenging landscape with emerging technologies."
- Moat: Neola Medical's proprietary technology provides a temporary competitive edge, but it is vulnerable to rapid innovation from larger players.
- growth - Investors looking for innovative medical technology with potential for high returns.
- Low - The company is currently debt-free, so rising interest rates do not impact financing costs…
- Watch on earnings: Regulatory approval timelines for new devices, Clinical trial success rates, Sales growth in European markets.
One Sentence Summary:
Neola Medical AB (publ): the story is balanced — regulatory approvals for new medical devices.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers